Study of Clinical Pharmacokinetics in Oncology Diseases
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: closed (20 October 2022) | Viewed by 3021
Special Issue Editors
Interests: cancer cell biology; mechanisms of cancer cell death; cancer stem cells; drug resistance; tumor microenvironment; microbiome and cancer; pharmacology; pharmacokinetics of antineoplastic drugs
Special Issues, Collections and Topics in MDPI journals
Interests: pharmacokinetics; pharmacometrics; antibacterial drugs; intensive care units; therapeutic drug monitoring
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Anticancer drugs have different pharmacokinetic profiles depending on their chemical structures and on the schedules used in clinical practice. Furthermore, antineoplastic agents may significantly interact with drugs that are used to treat co-morbidities in oncological patients. Therefore, the pharmacokinetics of anticancer drugs should be adequately described and investigated by the scientific literature in order to avoid severe adverse drug reactions and to maintain plasma drug concentrations within the therapeutic range. It is worth noting that the alteration of pharmacokinetic parameters may determine a therapeutic failure and a pharmacokinetic-based resistance to the treatment, reducing the survival of cancer patients and worsening quality of life. Relationships between systemic exposure to anticancer drugs, for example, those described by the area under the concentration–time curve, and both toxicity and response have been described for various classes of drugs. However, the relationship between pharmacokinetic parameters and the response rate is usually neglected for many anticancer drugs, and this may be related to the lack of studies describing this particular but fundamental aspect of anticancer pharmacology. The scientific community should prioritize the active therapeutic drug monitoring of anticancer drugs in order to rationalize the administration of these compounds. This is even more urgent in the paediatric field.
With this Special Issue, we hope to encourage submissions that discuss the current state-of-the-art, address ongoing knowledge gaps, and focus on ongoing controversies related to clinical pharmacokinetics in oncology diseases.
Prof. Dr. Guido Bocci
Prof. Dr. Antonello Di Paolo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antineoplastic drugs
- pharmacokinetics
- interindividual variability
- efficacy
- toxicity
- therapeutic drug monitoring
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
